Slide 1 of 18

Diabetes Mellitus Type 1

Advanced Medical Education

A comprehensive course on the pathophysiology, immunology, clinical management, and treatment strategies of Type 1 Diabetes Mellitus for healthcare professionals.

💡 Course Overview

This comprehensive course covers immune mechanisms, pancreatic beta cell dysfunction, clinical presentation, diagnostic criteria, and detailed insulin therapy and adjunctive management strategies for Type 1 Diabetes.

Slide 2 of 18

Definition & Epidemiology

Definition

Type 1 Diabetes Mellitus is a chronic autoimmune disorder characterized by selective destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in absolute insulin deficiency and chronic hyperglycemia.

Global Epidemiology

Global prevalence: Approximately 8.4 million people worldwide
Incidence: 15-400 cases per 100,000 per year (varies by region)
Age of onset: Peaks between 10-14 years; can occur at any age
Annual increase: 3-5% increase in incidence globally, particularly in developed countries
Genetic predisposition: 30-50% concordance in monozygotic twins
HLA association: 90% of patients carry HLA-DR3 or HLA-DR4 alleles

Etiopathogenesis

Genetic factors: HLA genes, PTPN22, INS, CTLA4, IL2RA polymorphisms
Environmental triggers: Viral infections, dietary factors, infections
Autoimmune progression: Progressive immune-mediated beta cell destruction
Staging model: Stage 1 (autoimmunity), Stage 2 (dysglycemia), Stage 3 (diabetes)

🔬 Key Point

Type 1 Diabetes represents an environmental trigger acting on genetically susceptible individuals, explaining the clustering of cases in certain populations and time periods.

Slide 3 of 18

Immunopathology & Beta Cell Destruction

Autoimmune Mechanisms

Type 1 Diabetes involves multiple autoimmune pathways targeting different beta cell antigens and mechanisms.

Healthy Beta Cells

Producing Insulin

Immune tolerance maintained

→

Autoimmune Attack

Beta Cell Loss

Progressive destruction

Key Autoimmune Targets

Antibody Targets

GAD65: Glutamic acid decarboxylase-65 (65% of patients)
ICA512/IA-2: Islet antigen-2 (60% of patients)
Insulin AB: Anti-insulin autoantibodies (70% of children)
ZnT8: Zinc transporter-8 (50% of patients)

Cellular Immunity

T-cell mediated: CD8+ cytotoxic T cells destroy beta cells
Th1 response: IFN-γ and TNF-α production
Th17 cells: IL-17 producing autoreactive cells
Regulatory T failure: Loss of immune tolerance

Stages of Beta Cell Destruction

Progression to Diabetes

Stage 1 - Autoimmunity: Positive autoantibodies, normal glycemia, normal beta cell function
Stage 2 - Dysglycemia: Positive autoantibodies + abnormal glucose tolerance (IGT or IFG)
Stage 3 - Diabetes: Symptomatic hyperglycemia, clinical presentation, <10% beta cell function remaining
Timeline: Variable from months to years; faster in young children, slower in adults

Environmental Triggers

Viral infections: Coxsackievirus, enterovirus, CMV, EBV (molecular mimicry)
Intestinal infections: Alter gut microbiome and intestinal barrier function
Dietary factors: Early cow's milk exposure, gluten, short chain fatty acids
Hygiene hypothesis: Reduced microbial exposure alters immune development

🧬 Remember

Type 1 Diabetes requires both genetic predisposition AND environmental triggers. Identical twins have 30-50% concordance, indicating environmental factors are essential for disease development.

Slide 4 of 18

Clinical Presentation & Diagnosis

Acute Presentation

Classic Symptoms

Polyuria (frequent urination)
Polydipsia (excessive thirst)
Polyphagia (increased hunger)
Weight loss (often sudden)
Fatigue and weakness
Irritability and mood changes

Diabetic Ketoacidosis (DKA)

Incidence: 15-30% at initial presentation
Symptoms: Nausea, vomiting, abdominal pain
Signs: Fruity breath, Kussmaul respiration, altered mental status
Mortality: 0.2-1% in developed countries
Medical emergency: Requires ICU admission

Diagnostic Criteria (ADA 2024)

Test	Diabetes Diagnostic Threshold	Prediabetes Range	Notes
Fasting Glucose	≥126 mg/dL	100-125 mg/dL	After 8-hour fast
2-Hour Glucose (OGTT)	≥200 mg/dL	140-199 mg/dL	75g glucose load
Random Glucose	≥200 mg/dL (+ symptoms)	N/A	With classic symptoms
HbA1c	≥6.5%	5.7-6.4%	Average 3-month glucose

Autoantibody Testing

Distinguishing Type 1 from Type 2

Anti-GAD65: Most common (80% of new-onset Type 1)
Anti-ICA512: IA-2 antibody, 60% positive
Anti-insulin: 70% in children <5 years
Anti-ZnT8: Emerging marker, 50% positive
Multiple positivity: 90% of Type 1 patients have 2+ autoantibodies

Associated Autoimmune Conditions

Thyroid disease: 20-30% of Type 1 patients (Graves' disease, Hashimoto's thyroiditis)
Celiac disease: 3-5% (screen with tissue transglutaminase antibodies)
Addison's disease: 0.5-1% (adrenal insufficiency)
Pernicious anemia: Vitamin B12 deficiency
PCOS: Higher prevalence in females with Type 1

🩺 Clinical Pearl

Any patient under 30 years with new-onset diabetes presenting with DKA or weight loss should be tested for autoantibodies to confirm Type 1 Diabetes and exclude Type 2 misdiagnosis.

Slide 5 of 18

Acute Complications

Diabetic Ketoacidosis (DKA)

⚠️ Life-Threatening Emergency

Laboratory Findings:

Glucose >250 mg/dL
Arterial pH <7.30
Bicarbonate <18 mEq/L
Positive serum/urine ketones
Anion gap >12

Clinical Presentation:

Kussmaul respiration (rapid, deep)
Fruity-smelling breath
Nausea and vomiting
Abdominal pain
Altered mental status

Management:

IV fluid resuscitation
Insulin drip (0.1 units/kg/hr)
Electrolyte monitoring
Treat precipitating cause
ICU monitoring

Hyperglycemic Hyperosmolar State (HHS)

Feature	DKA	HHS	Mixed DKA-HHS
Glucose (mg/dL)	>250	>600	250-600
pH	<7.30	>7.30	7.15-7.35
Bicarbonate (mEq/L)	<18	>15	10-15
Ketones	Large	Small/none	Moderate
Osmolality	<320	>320	320-340

Hypoglycemia

Mild-Moderate Hypoglycemia

Glucose: 54-70 mg/dL
Adrenergic symptoms: Shakiness, sweating, palpitations
Neuroglycopenic: Confusion, difficulty concentrating
Treatment: 15g fast carbs (glucose tablets, juice)
Follow-up: Retest in 15 minutes

Severe Hypoglycemia

Glucose:<54 mg/dL
Loss of consciousness: Seizures may occur
Altered cognition: Unable to self-treat
Treatment: Glucagon 1 mg IM/IV or 911
Prevention: Continuous glucose monitor (CGM)

Complications at Presentation

Infection: UTI, respiratory infections (often precipitant)
Puberty acceleration: Growth spurt, early menarche
Psychiatric issues: Depression, eating disorders, anxiety
Metabolic issues: Growth deceleration if poorly controlled

🚨 Emergency Recognition

DKA is present in 15-30% at diagnosis. Family education on warning signs (polyuria, fruity breath, rapid breathing) enables early recognition and hospital presentation.

Mid-Course Quiz

Knowledge Check

What is the primary autoimmune mechanism in Type 1 Diabetes?

A) Destruction of alpha cells by antibodies

B) Selective destruction of insulin-producing beta cells by CD8+ T cells and autoantibodies

C) Reduced production of glucagon

D) Insulin receptor dysfunction

💭 Think About

Consider which cells produce insulin and what immune mechanisms target them in autoimmune conditions.

Slide 7 of 18

Insulin Therapy - Fundamentals

💉

Insulin Replacement

Essential lifelong therapy for Type 1 Diabetes

Rationale

Absolute insulin deficiency:<10% residual beta cell function
Mandatory therapy: No alternative to insulin in Type 1 DM
Mimics physiology: Basal (background) + bolus (meal) insulin
Prevent complications: Hyperglycemia causes acute and chronic damage

Therapeutic Goals

Normalize glucose: Target HbA1c <7% (individualize)
Prevent hypoglycemia: Avoid severe, frequent events
Reduce complications: Microvascular and macrovascular
Quality of life: Flexibility, reduced burden

Types of Insulin

Insulin Type	Onset	Peak	Duration	Uses
Rapid-Acting Humalog, Novolog, Apidra	10-15 min	1-2 hours	3-5 hours	Meals, high glucose
Short-Acting (Regular) Humulin R, Novolin R	30 min	2-3 hours	5-8 hours	Less common, IV use
Intermediate-Acting (NPH) Humulin N, Novolin N	2-4 hours	4-10 hours	10-16 hours	Basal, twice daily
Long-Acting Lantus, Levemir, Toujeo, Tresiba	2-4 hours	Minimal/none	24+ hours	Basal once daily

Insulin Regimens

Multiple Daily Injections (MDI)

Basal: 1-2 injections long-acting insulin
Bolus: Rapid-acting at meals (3+ injections)
Total: 4-5 injections/day
Flexibility: Adjust bolus for carbs
Pros: Flexible, portable
Cons: Frequent injections

Continuous Subcutaneous Insulin Infusion (CSII/Pump)

Basal: Continuous infusion rate
Bolus: Programmed from pump at meals
Total: 1 infusion set change every 2-3 days
Flexibility: Temporary basal rates for activity
Pros: Most flexible, better HbA1c
Cons: Cost, site issues, DKA risk

Insulin Initiation in New Diagnosis

Starting dose: 0.5-1 unit/kg/day total (lower in honeymoon phase)
Distribution: 50% basal, 50% bolus initially
Titration: Adjust based on glucose patterns every 3-5 days
Honeymoon phase: Remission lasting weeks to months; some beta cell recovery
Goal: Achieve target glucose while minimizing hypoglycemia

💊 Clinical Pearl

Type 1 Diabetes requires insulin from diagnosis; no trial period without insulin is acceptable as it risks DKA and complications.

Slide 8 of 18

Advanced Insulin Management & Optimization

Carbohydrate Counting

Insulin-to-Carbohydrate Ratio (ICR)

Definition: Grams of carbohydrate covered by 1 unit of rapid-acting insulin
Example: 1:10 ratio = 1 unit covers 10g carbohydrate
Calculation: 500 rule ÷ total daily insulin = ICR
Individualization: Varies by person, time of day, activity level
Adjustment: Monitor glucose responses and modify ratios quarterly

Insulin Sensitivity Factor (ISF)

Correction Factor

Definition: mg/dL drop in glucose per 1 unit of insulin
Example: ISF 1:50 = 1 unit drops glucose 50 mg/dL
Calculation: 1800 rule ÷ total daily insulin = ISF
Clinical use: Calculate correction dose for high glucose
Formula: Correction dose = (Current glucose - Target glucose) ÷ ISF

Basal Insulin Titration

Glucose Pattern	Fasting Glucose	Bedtime Glucose	Action
Rising overnight	High (>150)	Normal	Increase bedtime/evening basal
Stable overnight	Normal (80-150)	Normal	Basal appropriate, continue
Falling overnight	Low (<80)	Normal	Decrease bedtime basal
Dawn phenomenon	Very High (>180)	Low (<120)	Increase morning basal or evening dose

Bolus Insulin Optimization

Mealtime bolus: Dose based on carbohydrate count and ICR
Correction bolus: For elevated pre-meal glucose (ISF calculation)
Combination dose: Mealtime + correction bolus
Extended bolus (square wave): For high-fat/protein meals (pumps only)
Timing: Inject 10-15 minutes before meal for better glucose control

Special Situations

Exercise

Reduce basal 20-50% during activity
Delay bolus, reduce amount
Extended hypoglycemia risk (24hr)
Monitor CGM continuously

Illness

NEVER skip basal insulin
Check glucose frequently
May need MORE insulin
Increase fluids, electrolytes

Travel

Carry extra insulin supplies
Adjust time zones carefully
Secure cool travel case
Medical identification

🎯 Clinical Pearl

The 500 rule and 1800 rule provide starting points for ICR and ISF, but individual adjustment based on glucose patterns is essential for optimal control.

Slide 9 of 18

Glucose Monitoring Technology

Self-Monitoring of Blood Glucose (SMBG)

Finger-Stick Testing

Frequency: 4-8 times daily (before/2 hours after meals, bedtime, before driving)
Accuracy: ±15% at glucose <100 mg/dL, ±5% at higher levels
Technique: Alternate fingers, use lancet device, adequate blood sample
Cost:$0.50-1.00 per strip (often covered by insurance)
Role: Calibration for CGM, verification of symptoms

Continuous Glucose Monitoring (CGM)

Available Systems

FreeStyle Libre: 14-day wear, reader or phone app
Dexcom G6/G7: 10-14 day wear, real-time alarms
Medtronic Guardian: 7-day wear, integration with pumps
Eversense: 90-day sensor, implanted under skin
Cost:$40-100/month, often covered by insurance

Clinical Benefits

Real-time glucose trends (arrows)
Detection of hypoglycemia at night
Reduced hypoglycemic episodes (20-30%)
Lower HbA1c without increased hypos
Improved quality of life and flexibility

Time in Range (TIR) Metrics

Metric	Target Range	Age Group	Clinical Significance
Time in Range (70-180 mg/dL)	>70%	All ages	Primary CGM outcome, predicts complications
Time Below 70 mg/dL	<4%	All ages	Hypoglycemic exposure, risk of seizure
Time Above 180 mg/dL	<25%	All ages	Hyperglycemic exposure, complications
Glucose Variability (CV)	<36%	All ages	Oscillation between highs/lows

HbA1c and Its Interpretation

Definition: Glycated hemoglobin, reflects average glucose over 3 months
Normal range:<5.7%
Diabetes diagnosis: ≥6.5%
Type 1 target:<7% (individualize, avoid hypoglycemia)
Limitation: Doesn't reflect glucose variability or hypoglycemic events
Testing: Fasting not required, every 3 months after adjustment

📊 Clinical Pearl

CGM has revolutionized Type 1 Diabetes management; TIR >70% at 70-180 mg/dL is now the primary outcome, replacing HbA1c as sole measure of control.

Slide 10 of 18

GLP-1 Agonists & Adjunctive Therapies

GLP-1 Receptor Agonists

🧬

GLP-1 Agonists

Increasingly used in Type 1 Diabetes as adjunct therapy

Mechanism of Action

Target: Glucagon-like peptide-1 receptor
Effect: Enhance glucose-dependent insulin secretion (less relevant in Type 1)
Gastrointestinal: Slow gastric emptying, reduce appetite
Additional: Weight loss, cardiovascular protection

Role in Type 1 Diabetes

Indication: Added when insulin alone insufficient or overweight
Benefit: Reduces insulin requirements by 10-20%
Weight loss: 2-5 kg reduction with therapy
Cardiovascular: Improved lipid profile, blood pressure

Available GLP-1 Agonists

Medication	Frequency	Starting Dose	Maintenance	Cost/Month
Liraglutide (Victoza)	Daily injection	0.6 mg	1.2-1.8 mg	$300-400
Dulaglutide (Trulicity)	Weekly injection	0.75 mg	1.5 mg	$350-450
Semaglutide (Ozempic)	Weekly injection	0.25 mg	0.5-1.0 mg	$400-500
Tirzepatide (Mounjaro)	Weekly injection	2.5 mg	5-15 mg	$500-600

Adverse Effects

Gastrointestinal

Nausea (50-80% initially)
Vomiting (10-30%)
Diarrhea or constipation
Abdominal pain
Mitigation: Slow titration, smaller meals

Serious Concerns

Pancreatitis (rare)
Medullary thyroid carcinoma (animal data)
C-cell hyperplasia risk
Hypoglycemia when combined with insulin
Monitoring: Blood lipase, glucose vigilance

Other Adjunctive Medications

SGLT-2 Inhibitors

Empagliflozin, dapagliflozin
Improve glycemic control
Weight loss, BP reduction
Caution: DKA risk

Metformin

Some benefit in insulin-resistant Type 1
Improved lipid profile
GI side effects common
Usually NOT indicated monotherapy

Pramlintide

Amylin analog
Delays gastric emptying
Reduces postprandial glucose
Hypoglycemia risk with insulin

💊 Clinical Pearl

GLP-1 agonists are increasingly used in Type 1 Diabetes not for their diminished insulinotropic effect, but for weight management and cardiovascular benefits when insulin causes weight gain.

Slide 11 of 18

Chronic Microvascular Complications

Diabetic Retinopathy

Pathophysiology and Screening

Incidence: 1/3 of Type 1 patients have some retinopathy after 20 years
Leading cause of blindness: In working-age adults
Stages: Nonproliferative → proliferative → advanced/neovascularization
Risk factors: Duration, hyperglycemia, hypertension, pregnancy
Prevention: Intensive glycemic control (↓47% risk), BP control
Screening: Annual dilated retinal exam starting 5 years post-diagnosis

Diabetic Nephropathy

Stage	Characteristics	UACR (mg/g creatinine)	eGFR (mL/min)
Stage 1 Hyperfiltration	Increased GFR, kidney growth	<30 (normal)	>90
Stage 2 Silent	GBM thickening, no proteinuria	<30	60-90
Stage 3 Incipient	Microalbuminuria appears	30-300	30-59
Stage 4 Overt	Proteinuria, declining GFR	>300	<30
Stage 5 ESRD	Kidney failure, dialysis needed	Very high	<15

Diabetic Neuropathy

Distal Symmetric Polyneuropathy (DSPN)

Most common: 50% at 25-year diabetes duration
Presentation: Paresthesias, numbness, burning feet
Symptoms: Worse at night, stocking-glove distribution
Complications: Foot ulcers, infections, amputations
Management: Tight glucose control, foot care, pain relief

Autonomic Neuropathy

Cardiovascular: Resting tachycardia, orthostatic hypotension
Gastrointestinal: Gastroparesis, diarrhea/constipation
Genitourinary: Erectile dysfunction, bladder dysfunction
Hypoglycemia unawareness: Impaired counter-regulatory response
Incidence: 20% at 20-year duration

Prevention Strategies

Glycemic control: Intensive therapy reduces complication risk by 50-80%
Blood pressure control: Target <130/80 mmHg (reduce nephropathy progression)
Lipid management: Statin therapy for cardiovascular protection
Screening: Annual urine albumin-to-creatinine ratio (UACR), dilated eye exam
Angiotensin system inhibitors: ACEi or ARB for microalbuminuria/proteinuria

🔍 Clinical Pearl

The Diabetes Control and Complications Trial (DCCT) showed intensive glucose control reduced retinopathy risk by 76%, nephropathy by 50%, and neuropathy by 60% compared to conventional therapy.

Slide 12 of 18

Macrovascular Disease & Cardiovascular Risk

Cardiovascular Risk in Type 1 Diabetes

Epidemiology

Leading cause of death: 50% of Type 1 mortality from CVD
Relative risk: 3-10x higher than non-diabetic population
Accelerated atherosclerosis: Manifests 10-15 years earlier
Gender disparity: Premenopausal women lose estrogen protection
Silent ischemia: Autonomic neuropathy masks angina symptoms

Atherosclerotic Cardiovascular Disease (ASCVD)

Condition	Mechanism	Presentation	Screening/Prevention
Coronary Artery Disease	Plaque deposition, inflammation	Chest pain/angina, MI	Stress test, aspirin, statin
Cerebrovascular Disease	Large vessel atherosclerosis	TIA, ischemic stroke	Carotid ultrasound, aspirin
Peripheral Artery Disease	Lower extremity atherosclerosis	Claudication, foot ulcers	Ankle-brachial index, foot care

Cardiovascular Risk Factors

Modifiable

Hyperglycemia (HbA1c)
Hypertension (>130/80)
Dyslipidemia (↑LDL, ↓HDL)
Smoking
Obesity (BMI >25)
Physical inactivity

Non-Modifiable

Age (>40 years)
Female gender
Diabetes duration
Family history CVD
Albuminuria/proteinuria

Diabetes-Specific

Albuminuria (marker)
Hyperinsulinemia
Endothelial dysfunction
Inflammation (CRP)
Oxidative stress

Preventive Strategies

Comprehensive Cardiovascular Risk Reduction

Glycemic control: Intensive therapy (TIR >70%), avoid hypoglycemia
Blood pressure: Target <130/80 mmHg, ACEi/ARB if albuminuria
Lipid management: High-intensity statin therapy, target LDL <70 mg/dL
Antiplatelet therapy: Aspirin 81-325 mg daily for secondary prevention
Lifestyle: Exercise 150 min/week, Mediterranean diet, smoking cessation
GLP-1 agonists: Shown to reduce cardiovascular events in Type 2; emerging benefit in Type 1

❤️ Clinical Pearl

Type 1 Diabetes patients have similar cardiovascular risk to Type 2 Diabetes patients; aggressive multifactorial risk reduction (glucose, BP, lipids) is essential.

Slide 13 of 18

Special Populations & Considerations

Pediatric Type 1 Diabetes

Unique Challenges

Diagnosis: Often DKA at presentation (50% in <5 years); dramatic symptoms
Insulin requirements: Variable; honeymoon phase common (weeks to months)
HbA1c targets:<7.5% recommended (balance control vs. hypoglycemia risk)
Hypoglycemia: Seizure risk, permanent brain damage if severe/repeated
Technology: CGM and pumps greatly improve management, recommended
Psychological: Burden of daily management, school accommodations, peer support

Adolescents with Type 1 Diabetes

Challenges

Rebellion/non-adherence common
Increased insulin resistance (pubertal)
Poor glycemic control often present
Disordered eating/eating disorders
Psychiatric comorbidities (depression, anxiety)
Risky behaviors (alcohol, drugs)

Strategies

Motivational interviewing
Shared decision-making
Mental health support/screening
Peer support groups
Transition planning (age 18-21)
Technology engagement

Pregnancy with Type 1 Diabetes

Phase	Target HbA1c	Insulin Needs	Monitoring
Preconception	<6.5%	Usually decrease (improved insulin sensitivity)	Monthly HbA1c, glycemic control
1st Trimester	<6.5%	May decrease further (hyperemesis)	CGM, weekly visits, avoid hypoglycemia
2nd-3rd Trimester	<6.5%	Increase 25-50% (insulin resistance)	Frequent glucose checks, fetal monitoring
Delivery	Individualize	IV insulin during labor, close glucose checks	Neonatal glucose screening

Adults (Established Diabetes)

Management Focus

Complication screening: Comprehensive annual assessments
Cardiovascular risk: Aggressive management (lipids, BP, glucose)
Psychological burden: Diabetes distress, depression common
Medication adherence: Simplification, cost considerations
Occupational safety: Driving safety, hypoglycemia awareness
Comorbidities: Common (thyroid, celiac, osteoporosis)

Elderly Patients with Type 1 Diabetes

Long diabetes duration: 40-50+ years, high complication prevalence
HbA1c targets: Less stringent (<8%) to avoid hypoglycemia
Hypoglycemia awareness: Often impaired; CGM and monitoring crucial
Frailty and falls: Hypoglycemia, impaired cognition increase fall risk
Polypharmacy: Drug interactions, kidney function changes
End-of-life care: De-intensification, comfort-focused approach appropriate

👨‍👩‍👧‍👦 Clinical Pearl

Type 1 Diabetes management must be individualized by age, life stage, and comorbidities; rigid targets can harm vulnerable populations.

Slide 14 of 18

Patient Education & Self-Management

Diabetes Self-Management Education (DSME)

Core Content Areas

Disease understanding: Pathophysiology, immune mechanisms, natural history
Insulin administration: Injection technique, pen use, pump operation
Carbohydrate counting: Label reading, portion estimation, meal planning
Glucose monitoring: SMBG, CGM use, interpretation of trends
Hypoglycemia management: Recognition, treatment, glucagon administration
Exercise and activity: Impact on glucose, prevention strategies
Sick day management: Never stop insulin, increase monitoring, hydration

Psychosocial Support

Screening for Mental Health

Depression screening (PHQ-9)
Anxiety assessment (GAD-7)
Eating disorders (especially young females)
Disordered eating/insulin restriction
Diabetes distress questionnaire
Referral: Behavioral health specialist

Support Resources

Support groups (in-person, online)
Diabetes camps for children/teens
Patient advocacy organizations (JDRF, ADA)
Mental health counseling
Family therapy/coaching
Diabetes technology training

Hypoglycemia Awareness Training

Critical Skills

Recognition: Adrenergic symptoms (shakiness, sweating), neuroglycopenic (confusion, slurred speech)
Prevention: Never skip meals, reduce insulin before exercise, regular glucose checks
Treatment: 15g fast carbs, wait 15 minutes, recheck, treat again if still <70
Glucagon rescue: Family/friend administration for severe hypoglycemia
Post-event analysis: What caused it? How prevent recurrence?

Sick Day Management

Action Item	Details	Rationale	When to Call Doctor
NEVER stop insulin	Continue basal even if unable to eat	Prevent DKA (sick = cortisol, reduced insulin effect)	If vomiting >30 min
Check glucose frequently	Every 1-2 hours, use CGM if available	Identify trends early, adjust dosing	If >300 mg/dL consistently
Increase fluids	Sugar-free beverages (water, broth)	Prevent dehydration, reduce glucose	If unable to keep down fluids
Monitor for DKA	Fruity breath, nausea, rapid breathing	Early recognition enables treatment	Seek emergency care immediately

Quality of Life Considerations

Burden of management: Daily injections, blood checks, carb counting
Dietary restrictions: Not strict; carb counting allows flexibility
Exercise: Can participate fully; plan for hypo prevention
School/work: Accommodations (snacks, breaks, peer understanding)
Transition to adult care: Shift from parent-managed to self-managed by age 18-21
Fertility and pregnancy: Can have healthy pregnancies with planning

👨‍⚕️ Clinical Pearl

Effective patient education improves outcomes more than any single medication; invest time in understanding barriers and motivators for each patient.

Slide 15 of 18

Immunotherapy & Future Directions

Immunosuppression Approaches

Anti-CD3 Therapy (Teplizumab)

Mechanism: Depletes/inactivates CD3+ T cells
Timing: Most effective early, Stage 1-2
Efficacy: Delays progression by ~2 years
FDA approved: 2022 for at-risk individuals
Side effects: Rash, lymphopenia, infection risk
Current role: Research/prevention; not routine treatment

Other Immunotherapies

GAD-alum (Diamyd): Glutamic acid decarboxylase peptide vaccine
BCG vaccine: Trained immunity approach
Checkpoint inhibitors: Anti-PD-L1, anti-CTLA-4
Regulatory T cells: Expansion/infusion strategies
Beta cell replacement: Stem cell-derived beta cells (future)
Development stage: Clinical trials ongoing

Pancreatic Transplantation

Type	Indication	Success Rate	Durability	Risks
Pancreas Transplant Alone (PTA)	Brittle diabetes, recurrent DKA	90% 1-year graft survival	Average 15-18 years	Rejection, surgical, immunosuppression
Simultaneous Kidney-Pancreas (SKP)	Type 1 + ESRD requiring transplant	95% success (immunosuppression benefit)	20+ years for both organs	Surgical, rejection, long-term meds
Pancreas After Kidney (PAK)	Type 1 with prior kidney transplant	80-85% graft survival	10-15 years average	Increased immunosuppression burden

Emerging Technologies

Artificial Pancreas (Closed-Loop)

CGM + insulin pump + algorithm
FDA-approved systems available
Reduces hypoglycemia, improves HbA1c
Still require user inputs
Fully automated versions in trials

Smart Insulin

Responds to glucose (pH-sensitive)
Reduced hypoglycemia risk
Earlier stages of development
May revolutionize safety

Beta Cell Replacement

Induced pluripotent stem cells
Lab-generated beta cells
Transplantation strategies
5-10 years to clinic

Prevention Strategies

Autoantibody screening: Identify Stage 1 for intervention
At-risk relative programs: Screen siblings, offspring
Environmental modification: Delayed cow's milk, probiotics (controversial)
Teplizumab for Stage 1: FDA-approved option for prevention
Research cohorts: Ongoing studies for additional interventions

🚀 Future Outlook

The next decade may see transition from pure insulin replacement toward disease-modifying therapies that preserve beta cell function or replace destroyed cells.

Slide 16 of 18

Clinical Guidelines & Evidence-Based Practice

ADA Standards of Medical Care 2024

Key Recommendations for Type 1 Diabetes

Diagnosis: HbA1c ≥6.5%, fasting ≥126, OGTT ≥200, or random with symptoms + autoantibodies
Glycemic targets: HbA1c <7% individualized; TIR >70% at 70-180 mg/dL
Insulin: Basal-bolus MDI or CSII; CGM strongly recommended
Education: DSME within 3 months of diagnosis and ongoing
Screening: Annual microalbumin, lipids, BP; retinal exam; mental health

ISPAD Clinical Practice Consensus Guidelines

Topic	Pediatric Recommendations	Evidence Level
Glycemic Control	HbA1c target <7.5%; individualize based on age, hypoglycemia risk	Strong
Insulin Therapy	Basal-bolus insulin; CSII or MDI; NPH acceptable if access limited	Strong
Glucose Monitoring	CGM recommended ≥1/day finger sticks; more frequent with poor control	Moderate
DKA Management	Pediatric ICU protocol; avoid overcorrection hyperosmolality, cerebral edema	Strong
Complications Screening	Retinal at 5 years post-diagnosis, annually; microalbumin annually	Strong

Quality Metrics & Outcomes Monitoring

Process Measures

HbA1c testing every 3 months
Annual complication screening
Psychosocial assessment completed
Insulin supply continuity
Technology access offered
DSME participation rate

Outcome Measures

HbA1c <7% achievement rate
TIR >70% (for CGM users)
Hypoglycemic event frequency
DKA hospitalization rate
Complication prevalence/incidence
Patients reporting satisfaction

Shared Decision-Making Framework

Discuss options: Insulin regimens (MDI vs. pump), CGM systems, technology preferences
Elicit preferences: Simplicity vs. flexibility, budget constraints, lifestyle
Provide evidence: Outcomes data, risk-benefit, expert recommendations
Agree on plan: Document goals, targets, monitoring schedule
Follow-up: Assess satisfaction, adjust as needed

📋 Clinical Pearl

Evidence-based guidelines provide frameworks, but individualization to patient values, resources, and life circumstances is essential for successful long-term management.

Final Assessment

Comprehensive Quiz - 10 Questions

Question 1 of 10

What is the primary autoimmune target in Type 1 Diabetes?

A) Alpha cells producing glucagon

B) Beta cells producing insulin

C) Delta cells producing somatostatin

D) Pancreatic acinar cells

📝 Assessment

This comprehensive quiz covers all major topics from the course. Take your time and think through each question carefully.

Course Complete

Congratulations!

🚀 Next Steps

Continue advancing your expertise by applying these evidence-based principles in clinical practice and staying engaged with the Type 1 Diabetes community.